AMPLUSBIO PHARMA S.R.L.

The gap between scientific discovery in the lab and the development of a drug ready for the clinic is one of the hardest to cross in the biopharmaceutical sector. Many brilliant ideas generated through academic research never find their way to therapeutic application, for lack of entrepreneurial expertise, industry networks, or patient capital willing to fund the riskiest phase of translation. AMPLUSBIO PHARMA, a Naples-based startup, positions itself as the bridge between these two worlds. Through the operational model developed with Materias, the company builds an integrated approach that spans from the initial assessment of research opportunities all the way through to scale-up. A team of experts analyzes the scientific and market potential of a project, validates it through industry partnerships, and supports the acceleration of investment in subsequent stages. This model combines the function of a technology accelerator with that of a strategic partner for research valorization. The target market is early-stage biopharmaceutical research, with particular attention to projects originating in academic or institutional research settings that need a structured pathway to reach industrial validation. The reference ecosystem includes universities, research centers, scientific foundations, and biopharmaceutical spin-offs seeking support to transform their discoveries into developable drug candidates. The business model is B2B, based on customized services and solutions. The value proposition is not that of a simple consultant, but of a partner that brings multidisciplinary expertise — scientific, regulatory, financial, and industrial — in an integrated way, substantially increasing the likelihood that a promising research project will actually reach the patient.